{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:20:18Z","timestamp":1772504418834,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Skin diseases induced by Sintilimab, a programmed cell death protein-1 (PD-1) inhibitor, are rare, with only 28 cases reported. We provide a literature review on skin diseases associated with Sintilimab and summarize the patient\u2019s primary disease, duration of Sintilimab use, treatment, and disease progression. This study aims to improve understanding of Stevens\u2013Johnson syndrome (SJS) induced by this monoclonal antibody and its treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>We report a case of SJS induced by Sintilimab in a patient treated at our hospital. The patient exhibited widespread erythema, papules, and vesicles, accompanied by mucosal erosion and exudation in the oral cavity, eyes, urethral orifice, and perianal region. The patient was immediately treated with intravenous methylprednisolone sodium succinate (40 mg\/day), antihistamines, and supportive care, including fluid replacement and wound care. His symptoms gradually improved, and he was discharged after 20 days. At the 6-month follow-up, he remained stable, with no recurrence of symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although severe drug rash, including SJS, caused by PD-1 inhibitors is relatively uncommon, its underlying molecular pathogenesis remains unclear. Physicians should remain vigilant regarding potential adverse reactions when prescribing Sintilimab. If severe reactions occur, discontinuation of chemotherapy and immediate administration of adequate corticosteroids with symptomatic support can help reduce morbidity and mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1568316","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T05:25:58Z","timestamp":1747891558000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Stevens\u2013Johnson syndrome induced by Sintilimab: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Huan","family":"Kuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DongBei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChuXiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LiPing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZiYu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XunJin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HongRong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by Pd-1\/Pd-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan Ocular Toxicol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1762561","article-title":"Toripalimab for the treatment of melanoma","volume":"20","author":"Tang","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (Iraes) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.883121","article-title":"Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Dobry","year":"2022","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.003","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology-thirty years of progress but still much to be done","volume":"137","author":"Stern","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4317\/jced.53653","article-title":"Erythema multiforme induced by alendronate sodium in a geriatric patient: A case report and review of the literature","volume":"9","author":"de Arruda","year":"2017","journal-title":"J Clin Exp Dent"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2569","article-title":"Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics","volume":"97","author":"Siedner-Weintraub","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20515","article-title":"Current agreement on the management of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"185","author":"Chen","year":"2021","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"Scorten: A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.912168","article-title":"Case report: sintilimab-induced Stevens-Johnson syndrome in a patient with advanced lung adenocarcinoma","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4103\/ds.DS-D-23-00082","article-title":"Genetic associations of human leukocyte antigen alleles in cutaneous delayed drug hypersensitivity reactions: An updated review","volume":"41","author":"Chen","year":"2023","journal-title":"Dermatol Sin"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: A prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol: EJD"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2024.09.005","article-title":"Downregulation of carnitine acetyltransferase by promoter hypermethylation regulates ultraviolet-induced matrix metalloproteinase-1 expression in human dermal fibroblasts","volume":"116","author":"Song","year":"2024","journal-title":"J Dermatol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a Pan-European multicenter study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1691-4","DOI":"10.16766\/j.cnki.issn.1674-4152.2017.10.016","article-title":"Clinical analysis of 73 cases of severe erythema multiform and toxic epidermal necrolysis","volume":"15","author":"Ye","year":"2017","journal-title":"Chinese Journal of General Practice"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.14053\/j.cnki.ppcr.202309016","article-title":"A case of toxic epidermal necrolysis caused by cindilizumab and treatment countermeasures","volume":"26","author":"Zha","year":"2023","journal-title":"Practical Pharmacy and Clinical Remedies"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e35659","DOI":"10.1097\/md.0000000000035659","article-title":"Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.989966","article-title":"Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S401286","article-title":"Adalimumab for sintilimab-induced toxic epidermal necrolysis in a patient with metastatic gastric Malignancy: A case report and literature review","volume":"16","author":"Zhang","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0074","article-title":"Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review","volume":"14","author":"Yang","year":"2022","journal-title":"Immunotherapy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S353743","article-title":"Treatment of Pd-1 inhibitor-associated toxic epidermal necrolysis: A case report and brief review","volume":"15","author":"Zhao","year":"2022","journal-title":"OncoTargets Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2096-3327.2022.09.012","article-title":"A case of severe skin immunotoxicity and the literature","volume":"19","author":"Tian","year":"2022","journal-title":"China Journal of Rational Drug Use"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e15663","DOI":"10.1111\/dth.15663","article-title":"A case of sintilimab-induced Sjs\/Ten: dermatologic adverse reactions associated with programmed cell death protein-1 inhibitors","volume":"35","author":"Huang","year":"2022","journal-title":"Dermatol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/jir.S427336","article-title":"Toxic epidermal necrolysis and Stevens - Johnson syndrome following sintilimab administration in a non-small cell lung cancer patient: A case report","volume":"16","author":"Jiang","year":"2023","journal-title":"J Inflammation Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231173556","article-title":"A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma","volume":"51","author":"Gong","year":"2023","journal-title":"J Int Med Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.707967","article-title":"Case report: A case report and literature review on severe bullous skin reaction induced by anti-Pd-1 immunotherapy in a cervical cancer patient","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.13735\/j.cjdv.1001-7089.202109096","article-title":"Two cases of toxic epidermal necrolysis caused by PD-1 inhibitor and literature review","volume":"36","author":"Li","year":"2022","journal-title":"Chinese Journal of Dermatovenereology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1065137","article-title":"Case report: toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1124730","article-title":"Case report: bullous pemphigoid associated with sintilimab therapy for Pmmr\/Mss colorectal cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B33","article-title":"PD-1 inhibitor causes bullous pemphigoid in 3 cases reports and literature analysis","volume":"31","author":"Sun","year":"2022","journal-title":"Chin J New Drug"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.14109\/j.cnki.xyylc.2022.04.13","article-title":"Sindilizumab treated advanced lung adenocarcinoma causing bullous dermatitis in a case","volume":"41","author":"Yan","year":"2022","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S374449","article-title":"A case of systemic severe bullous pemphigoid caused by long-term sintilimab treatment for renal cell carcinoma","volume":"15","author":"He","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7539\/j.issn.1672-2981.2022.09.043","article-title":"Vitiligo-like depigmentation caused by cindilizumab in one case and literature review","volume":"20","author":"Yu","year":"2022","journal-title":"Central South Pharmacy"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.13267\/j.cnki.syzlzz.2023.075","article-title":"PD-1-antibody treatment of lung cancer showed a case of vitiligo-like skin reaction and immune checkpoint inhibitor-related pneumonia","volume":"38","author":"Wang","year":"2023","journal-title":"Journal of Practical Oncology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.13748\/j.cnki.issn1007-7693.2021.19.015","article-title":"A case of vitiligo caused by Sindilizumab injection","volume":"38","author":"Zhang","year":"2021","journal-title":"Chinese Journal of Modern Applied Pharmacy"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1099108","article-title":"Case report: immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data","volume":"12","author":"Rao","year":"2022","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.13286\/j.1001-5213.2022.12.22","article-title":"Rare purpuroid cutaneous vasculitis caused by cindilizumab","volume":"42","author":"Wu","year":"2022","journal-title":"Chinese Journal of Hospital Pharmacy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e35946","DOI":"10.1097\/md.0000000000035946","article-title":"Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review","volume":"102","author":"Huang","year":"2023","journal-title":"Medicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.21037\/atm-22-5925","article-title":"Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: A case report and review of the literature","volume":"10","author":"Yan","year":"2022","journal-title":"Ann Trans Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.explore.2023.02.008","article-title":"Successful treatment of immune-related lichenoid dermatitis by weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature","volume":"19","author":"Liu","year":"2023","journal-title":"Explore (New York NY)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000473","article-title":"Sintilimab-induced alopecia universalis in a patient with the anti-tumor effect of complete remission after hepatectomy","volume":"46","author":"Wen","year":"2023","journal-title":"J Immunother (Hagerstown Md: 1997)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-1264.2022.01.21","article-title":"Cutaneous immune adverse reactions in advanced esophageal cancer","volume":"12","author":"Zeng","year":"2022","journal-title":"Anti-Tumor Pharmacy"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1568316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T05:26:10Z","timestamp":1747891570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1568316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":45,"alternative-id":["10.3389\/fonc.2025.1568316"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1568316","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"article-number":"1568316"}}